These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 35364607

  • 1. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
    Carter BZ, Mak PY, Tao W, Zhang Q, Ruvolo V, Kuruvilla VM, Wang X, Mak DH, Battula VL, Konopleva M, Jabbour EJ, Hughes PE, Chen X, Morrow PK, Andreeff M.
    Mol Cancer Ther; 2022 Jun 01; 21(6):879-889. PubMed ID: 35364607
    [Abstract] [Full Text] [Related]

  • 2. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, Leverson JD, Sampath D, Ferreira-Gonzalez A, Grant S.
    Cancer Res; 2018 Jun 01; 78(11):3075-3086. PubMed ID: 29559471
    [Abstract] [Full Text] [Related]

  • 3. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
    Satta T, Li L, Chalasani SL, Hu X, Nkwocha J, Sharma K, Kmieciak M, Rahmani M, Zhou L, Grant S.
    Clin Cancer Res; 2023 Apr 03; 29(7):1332-1343. PubMed ID: 36652560
    [Abstract] [Full Text] [Related]

  • 4. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.
    Carter BZ, Mak PY, Tao W, Ayoub E, Ostermann LB, Huang X, Loghavi S, Boettcher S, Nishida Y, Ruvolo V, Hughes PE, Morrow PK, Haferlach T, Kornblau S, Muftuoglu M, Andreeff M.
    Blood Cancer J; 2023 Apr 24; 13(1):57. PubMed ID: 37088806
    [Abstract] [Full Text] [Related]

  • 5. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M, Birsen R, Belhadj M, Huynh T, Cantero Aguilar L, Grignano E, Haddaoui L, Guillonneau F, Mayeux P, Hunault M, Tamburini J, Kosmider O, Fontenay M, Bouscary D, Chapuis N.
    Eur J Haematol; 2020 Nov 24; 105(5):588-596. PubMed ID: 32659848
    [Abstract] [Full Text] [Related]

  • 6. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
    Ewald L, Dittmann J, Vogler M, Fulda S.
    Cell Death Dis; 2019 Dec 04; 10(12):917. PubMed ID: 31801941
    [Abstract] [Full Text] [Related]

  • 7. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
    Wang X, Mak PY, Mu H, Tao W, Rao A, Visweswaran R, Ruvolo V, Pachter JA, Weaver DT, Andreeff M, Xu B, Carter BZ.
    Mol Cancer Ther; 2020 Aug 04; 19(8):1636-1648. PubMed ID: 32404407
    [Abstract] [Full Text] [Related]

  • 8. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
    Liu F, Zhao Q, Su Y, Lv J, Gai Y, Liu S, Lin H, Wang Y, Wang G.
    Exp Hematol; 2022 Jan 04; 105():39-49. PubMed ID: 34767916
    [Abstract] [Full Text] [Related]

  • 9. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
    Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, Cory S.
    Cell Death Differ; 2019 Jul 04; 26(7):1316-1331. PubMed ID: 30470795
    [Abstract] [Full Text] [Related]

  • 10. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C, Friess T, Birzele F, Kiialainen A, Dangl M.
    J Hematol Oncol; 2016 Jun 28; 9(1):50. PubMed ID: 27353420
    [Abstract] [Full Text] [Related]

  • 11. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R, Allen KJH, Dawicki W, Geoghegan EM, Ludwig DL, Dadachova E.
    Cancer Med; 2021 Feb 28; 10(3):1128-1140. PubMed ID: 33347715
    [Abstract] [Full Text] [Related]

  • 12. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
    Zhai Y, Tang Q, Fang DD, Deng J, Zhang K, Wang Q, Yin Y, Fu C, Xue SL, Li N, Zhou F, Yang D.
    Clin Cancer Res; 2023 Jan 04; 29(1):183-196. PubMed ID: 36240005
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y.
    Clin Cancer Res; 2019 Nov 15; 25(22):6815-6826. PubMed ID: 31320594
    [Abstract] [Full Text] [Related]

  • 14. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.
    Moujalled DM, Brown FC, Chua CC, Dengler MA, Pomilio G, Anstee NS, Litalien V, Thompson E, Morley T, MacRaild S, Tiong IS, Morris R, Dun K, Zordan A, Shah J, Banquet S, Halilovic E, Morris E, Herold MJ, Lessene G, Adams JM, Huang DCS, Roberts AW, Blombery P, Wei AH.
    Blood; 2023 Feb 09; 141(6):634-644. PubMed ID: 36219880
    [Abstract] [Full Text] [Related]

  • 15. Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
    Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS.
    J Clin Invest; 2023 Nov 15; 133(22):. PubMed ID: 37751299
    [Abstract] [Full Text] [Related]

  • 16. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, Dengler MA, Litalien V, MacRaild S, Chen M, Anstee NS, Reljić B, Gabriel SS, Djajawi TM, Riffkin CD, Aubrey BJ, Chang C, Tai L, Xu Z, Morley T, Pomilio G, Bruedigam C, Kallies A, Stroud DA, Bajel A, Kluck RM, Lane SW, Schoumacher M, Banquet S, Majewski IJ, Strasser A, Roberts AW, Huang DCS, Brown FC, Kelly GL, Wei AH.
    Blood; 2021 May 20; 137(20):2721-2735. PubMed ID: 33824975
    [Abstract] [Full Text] [Related]

  • 17. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
    Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, Leutz B, Adamia S, Zhu H, Kuang Y, Mogili A, Louissaint A, Bohl SR, Kim AS, Mehta AK, Sanghavi S, Wang Y, Morris E, Halilovic E, Paweletz CP, Weinstock DM, Garcia JS, Letai A.
    Cancer Cell; 2020 Dec 14; 38(6):872-890.e6. PubMed ID: 33217342
    [Abstract] [Full Text] [Related]

  • 18. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Moujalled DM, Pomilio G, Ghiurau C, Ivey A, Salmon J, Rijal S, Macraild S, Zhang L, Teh TC, Tiong IS, Lan P, Chanrion M, Claperon A, Rocchetti F, Zichi A, Kraus-Berthier L, Wang Y, Halilovic E, Morris E, Colland F, Segal D, Huang D, Roberts AW, Maragno AL, Lessene G, Geneste O, Wei AH.
    Leukemia; 2019 Apr 14; 33(4):905-917. PubMed ID: 30214012
    [Abstract] [Full Text] [Related]

  • 19. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
    Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, Vänttinen I, Nygren P, Klievink J, Bouhlal J, Pölönen P, Zhang Q, Adnan-Awad S, Mancebo-Pérez C, Saad J, Miettinen J, Javarappa KK, Aakko S, Ruokoranta T, Eldfors S, Heinäniemi M, Theilgaard-Mönch K, Wartiovaara-Kautto U, Keränen M, Porkka K, Konopleva M, Wennerberg K, Kontro M, Heckman CA, Mustjoki S.
    Blood; 2023 Mar 30; 141(13):1610-1625. PubMed ID: 36508699
    [Abstract] [Full Text] [Related]

  • 20. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition.
    Carter BZ, Mak PY, Tao W, Warmoes M, Lorenzi PL, Mak D, Ruvolo V, Tan L, Cidado J, Drew L, Andreeff M.
    Haematologica; 2022 Jan 01; 107(1):58-76. PubMed ID: 33353284
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.